Open, randomized, active-controlled insulin resistance outcome trial of safety and efficacy with empagliflozin in type 2 diabetic patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 03 Jul 2017 Planned End Date changed from 30 Mar 2017 to 30 Mar 2018.
- 03 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 27 May 2016 New trial record